Company: BIVIW
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001520138-25-000144
Chunk: 98

Company: BIOVIE INC.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 2
Chunk 98
---
 of approximately $678,000, resulting from declining use of consultants as the clinical studies
were completed, a decrease in Chemistry, Manufacturing and Controls (“CMC”) and new drug discovery totaling approximately
$354,000, a reduction in the use of regulatory and other consultants totaling approximately $29,000, and a decrease in related expenses
of approximately $18,000 in travel, conferences and publications.

The table below summarizes the expenses incurred for
the three months ended March 31, 2025 and 2024 by study:

    Three Months Ended  
    Three Months Ended  
    Increase 

    March 31, 2025  
    March 31, 2024  
    (Decrease) 

    Current Studies 

    Liver Program Phase 3 
    $95,323  
    $41,685  
    $53,638 
  
    Sunrise PD Phase 2 
     965,888  
     -  
     965,888 
  
    Long Covid Program, net of 2.5 million reimbursement 
     (1,087,734) 
     -  
     (1,087,734)
  
    Investigator-Initiated studies 
     12,025  
     9,199  
     2,826 

    $(14,498) 
    $50,884  
    $(65,382)

    Completed Studies 

    Ascites BIV201 Phase 2b 
    $-  
    $89,667  
    $(89,667)
  
    AD mild to moderate pivotal Phase 3 
     (26,091) 
     2,715,662  
     (2,741,753)
  
    Investigator-Initiated studies 
     -  
     1,928  
     (1,928)
  
    Other studies in development/cancelled 
     -  
     116,047  
     (116,047)

    $(26,091) 
    $2,923,304  
    $(2,949,395)

 23 

Selling, General and Administrative Expenses

Selling, general and administrative expenses were approximately $1.6 million and $2.0 million
for the three months ended March 31, 2025 and 2024, respectively. The net decrease in expenses of approximately $388